Predictive Oncology Inc. POAI Archives - Page 18 of 19

FridayNov 08, 2019 10:04 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Officer Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project

Helomics chief technology officer speaks at inaugural UK 100,000 Genomes Project Conference The 100,000 Genomes Project is a UK-government project, sequenced whole genomes from National Health Service patients The depth of the project data is best in class, yielding useful benchmarks to help validate Helomics models Dr. Mark Collins, chief technology officer of Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics subsidiary, recently spoke at the inaugural UK 100,000 Genomes Project Conference. Collins presented initial findings from Helomics’ analysis of UK 100,000 Genomes Project (“UK100K GP”) data toward Helomics’ goal of building AI-driven predictive models of ovarian cancer. The inaugural conference was…

ThursdayNov 07, 2019 10:23 am

Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine

Predictive Oncology is at forefront of growing trend of precision medicine The company applies smart tumor profiling, AI platform to extensive genomic and biomarker patient data sets POAI has large amounts of historical, standardized patient data from clinical testing that can be leveraged immediately The moment has come for Predictive Oncology Inc. (NASDAQ: POAI). A knowledge-driven, precision-medicine company, POAI focuses on applying data and artificial intelligence to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve clinical outcomes…

ThursdayOct 31, 2019 10:08 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves First Milestone in Cancer Quest 2020 Project

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced that its Helomics subsidiary has begun to sequence tumor cases from its collaboration with the UPMC Magee Women’s Hospital (http://ibn.fm/b9BBo). According to the update, the Helomics and UPMC Magee partnership focuses on analyzing the genomic and drug response profiles of women with ovarian cancer to build AI-driven predictive models’ terms of therapy response. A key benchmark in Predictive Oncology’s Cancer Quest 2020 project, the collaboration takes a retrospective look at around 400 ovarian cancer cases that Helomics profiled for drug response,…

WednesdayOct 30, 2019 11:50 am

Predictive Oncology Inc.’s (NASDAQ: POAI) Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow

Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments Like Amazon’s customer dataset, POAI’s deep database of historical tumor information positions it for industry success Precision medicine is a data problem – demonstrates the huge value of data and those companies that generate it When shopping on Amazon, it seems like the multinational technology company knows its customers intimately. Every product filtered into a search query response seems carefully curated to match each customer. This ability to leverage big data has pushed…

MondayOct 28, 2019 3:19 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale

Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that its Skyline Medical Division completed the sale of 10 STREAMWAY(R) Systems to a major New York hospital (http://ibn.fm/dXHwp). An article discussing the company reads, “For Predictive Oncology, this announcement represents a significant financial milestone. As POAI’s largest single-hospital transaction ever, the sale indicates the credibility and trust the STREAMWAY System is building within the industry. In addition, the sale is another positive indication that Skyline Medical, a POAI subsidiary, provides tremendous qualitative, long-term potential as it continues to focus…

ThursdayOct 24, 2019 11:33 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Division to Present Initial Findings of UK 100,000 Genomes Project Data at Inaugural Conference

Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that Helomics CTO Dr. Mark Collins will speak during the scientific session of the inaugural UK 100,000 Genomes Project (“UK100K GP”) conference, and will participate in an invite-only session on the expansion of the UK100K GP to 5 Million genomes. According to the update, Helomics partnered with the UK100K GP in November 2018 to utilize whole genome and outcome data from the project to advance its efforts to build predictive models of various cancers. “This partnership is key to our…

FridayOct 18, 2019 3:16 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Utilizing Artificial Intelligence, Smart Tumor Profiling to Augment Clinical Outcomes

Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response and improve clinical outcomes for cancer patients. An article discussing the company’s activities further reads, “Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient-derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test…

FridayOct 11, 2019 2:22 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project

Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (‘UK100K’) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole-genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes.…

WednesdayOct 09, 2019 11:50 am

Predictive Oncology Inc. (NASDAQ: POAI) Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System

POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, long-term potential In a significant announcement that bodes well for the company, Predictive Oncology Inc. (NASDAQ: POAI) announced that its Skyline Medical Division, producer of the STREAMWAY(R) System, has completed the sale of 10 systems to a major New York hospital (http://ibn.fm/dXHwp). The sale exceeds POAI’s largest single-hospital sale to date, and it is anticipated that the systems collectively will handle…

TuesdayOct 08, 2019 1:39 pm

Predictive Oncology Inc. (NASDAQ: POAI) Continues to Innovate to Improve Outcomes for Cancer Patients

POAI is leveraging the potential of AI and smart tumor profiling to predict tumor drug response TumorGenesis is developing innovative techniques for growing tumors in laboratory settings Helomics uses vital information from patients’ own living tumors to assist oncologists in selecting the most effective treatments Predictive Oncology Inc. (NASDAQ: POAI) is harnessing the power of artificial intelligence (AI) and rich information from patients’ own tumors to improve outcomes for cancer patients. Predictive Oncology applies its proprietary smart tumor profiling and AI platform to extensive genomic and biomarker patient datasets in order to predict tumor drug response and improve clinical outcomes…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI